How do you approach initial treatment of unresectable, locally advanced ER+, HER2-negative male breast cancer?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Iowa • HR+ • NCI-CCC Breast Tumor Board Question

CDK4/6i with endocrine therapy vs chemotherapy? Staging scans with no distant metastases. Male patient with neglected, fungating breast tumor with large palpable axillary LN mets.

Related Questions

How do you manage adjuvant endocrine therapy for microinvasive HR-positive disease measuring >=1mm in extension?

What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?

In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?

Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?

In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?

Would you offer capecitabine re-challenge for a patient with metastatic breast cancer and a history of coronary vasospasm?

In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?

Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?

What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?